Genelux Corporation
- Open
- 2.61
- Day high
- 2.61
- Day low
- 2.50
- Prev close
- 2.55
- Volume
- 83K
- Mkt cap
- $115M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 7.2
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$48K over the last 3 months (0 open-market buys, 4 sales)
- 🏛Institutions reducing (13F)
Genelux Corporation (GNLX) is a Healthcare company listed on NASDAQ. The stock is down 21% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 4 sales (SEC Form 4).
Genelux Corporation (GNLX) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
GNLX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 13, 2026 | $-0.20 | $-0.21 | -6.8% | — | — |
| May 7, 2026 | $-0.18 | $-0.20 | -11.1% | — | — |
| Mar 19, 2026 | $-0.22 | $-0.24 | -9.1% | $8000 | +0.0% |
| Nov 5, 2025 | $-0.23 | $-0.21 | +8.7% | — | — |
| Aug 7, 2025 | $-0.22 | $-0.20 | +9.1% | — | — |
| Mar 28, 2025 | $-0.17 | $-0.26 | -52.9% | $452000 | — |
| Nov 14, 2024 | $-0.19 | $-0.19 | +0.0% | — | — |
| Aug 14, 2024 | $-0.19 | $-0.22 | -15.8% | — | — |
| May 9, 2024 | $-0.23 | $-0.29 | -26.1% | $8000 | — |
| Nov 14, 2023 | $-0.12 | $-0.20 | -66.7% | — | — |
| Aug 14, 2023 | $-0.15 | $-0.23 | -53.3% | — | — |
| May 15, 2023 | $-0.16 | $-0.53 | -230.9% | $170000 | +0.0% |
GNLX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 4, 2026 | Yu Yongofficer: Chief Scientific Officer | Sell | 653 | $2.94 |
| Aug 4, 2026 | Cappello Josephofficer: Chief Technical Officer | Sell | 653 | $2.95 |
| Aug 4, 2026 | Zindrick Thomasofficer: President and CEO | Sell | 3,023 | $2.95 |
| Jul 2, 2026 | Smither John Wdirector | Sell | 12,000 | $2.91 |
| Jun 18, 2026 | Smither John Wdirector | Grant | 28,409 | — |
| Jun 18, 2026 | Smither John Wdirector | Grant | 31,566 | $3.03 |
| Jun 18, 2026 | Thomas Johndirector | Grant | 31,566 | $3.03 |
| Jun 18, 2026 | Mirabelli Marydirector | Grant | 28,409 | — |
| Jun 18, 2026 | Mirabelli Marydirector | Grant | 31,566 | $3.03 |
| Jun 18, 2026 | Yu Yongofficer: Chief Scientific Officer | Grant | 119,318 | — |
| Jun 18, 2026 | Pulisic Matthewofficer: Chief Financial Officer | Grant | 278,906 | — |
| Jun 18, 2026 | Groen Ericofficer: General Counsel | Grant | 233,957 | — |
| Jun 18, 2026 | Cappello Josephofficer: Chief Technical Officer | Grant | 174,841 | — |
| Jun 18, 2026 | Tyree James Ldirector | Grant | 28,409 | — |
| Jun 18, 2026 | Tyree James Ldirector | Grant | 31,566 | $3.03 |
Source: GNLX SEC Form 4 filings, latest Aug 4, 2026. For informational purposes only — not investment advice.
See the full GNLX insider & 13F page →Genelux Corporation company profile
Overview
Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biopharmaceutical company founded in 2001 and headquartered in Westlake Village, California. The company went public in January 2023 and specializes in developing innovative oncolytic viral immunotherapies designed to treat aggressive and difficult-to-treat solid tumors. Genelux represents a new frontier in cancer treatment, utilizing genetically modified viruses that can selectively target and destroy cancer cells while potentially stimulating the patient's immune system to fight the disease.
Business
Genelux operates in the biotechnology sector, specifically focusing on oncolytic viral immunotherapy - a cutting-edge approach to cancer treatment that uses modified viruses to attack cancer cells. Unlike traditional chemotherapy or radiation that can harm healthy cells, oncolytic viruses are engineered to preferentially infect and replicate within cancer cells, causing them to burst and die while leaving normal cells largely unharmed. The company's lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus (the same virus family used in smallpox vaccines) that has been engineered for treating ovarian cancer and non-small-cell lung cancer. Vaccinia virus is particularly well-suited for this application because it has a large genome that can accommodate therapeutic genes, replicates efficiently in cancer cells, and has a well-established safety profile from decades of use in vaccines. Beyond Olvi-Vec, Genelux is developing two additional therapeutic platforms. V2ACT Immunotherapy is being developed specifically for pancreatic cancer treatment, while V-VET1 is designed to treat both hematologic cancers (blood cancers like leukemia and lymphoma) and solid tumors. The company generates minimal revenue currently, with only $8,000 in total revenue for fiscal year 2024, as it remains in the pre-commercial clinical development stage typical of early-stage biotechnology companies.
Revenue model
As a clinical-stage biopharmaceutical company, Genelux currently operates on a research and development model with virtually no commercial revenue. The company's minimal revenue of $8,000 in 2024 likely comes from research collaborations, licensing arrangements, or government grants rather than product sales. The primary business model will eventually center on product sales of approved cancer therapies to hospitals, cancer treatment centers, and healthcare systems, with revenue generated through direct sales or licensing partnerships with larger pharmaceutical companies. The company's financial sustainability currently depends entirely on raising capital through equity financing, as evidenced by its ability to maintain operations despite burning approximately $21-29 million annually in operating cash flow. Paying customers will ultimately be healthcare providers treating cancer patients, with reimbursement coming from insurance companies and government healthcare programs like Medicare and Medicaid. Several factors could significantly impact Genelux's future margins and profitability. Positive clinical trial results demonstrating safety and efficacy would dramatically increase the company's value and ability to command premium pricing for its therapies. Conversely, negative trial results or regulatory setbacks could severely impact the company's prospects. The competitive landscape in oncology is intense, with major pharmaceutical companies and other biotechnology firms developing competing cancer immunotherapies. Manufacturing costs for viral therapies can be substantial, requiring specialized facilities and quality control processes. Additionally, the regulatory pathway for novel viral therapies involves extensive clinical testing and FDA approval processes that can take years and cost hundreds of millions of dollars.
Competitive moat
Genelux operates in a highly competitive biotechnology landscape where sustainable competitive advantages are difficult to establish and maintain. The company's primary potential moat lies in its proprietary viral engineering technology and specific modifications made to the vaccinia virus platform. However, this moat is relatively narrow and vulnerable to competition from larger pharmaceutical companies with greater resources and established oncology franchises. The company's intellectual property portfolio around its modified vaccinia virus strains provides some protection, but the biotechnology industry is notorious for patent challenges and the ability of competitors to engineer around existing patents. Major pharmaceutical companies like Merck, Bristol Myers Squibb, and Roche have substantial resources to develop competing oncolytic viral therapies or acquire promising smaller companies in the space. The regulatory pathway itself creates some temporary competitive protection - once Genelux advances through clinical trials and potentially gains FDA approval, competitors would need to conduct their own lengthy and expensive clinical programs. However, this advantage is time-limited and depends entirely on successful execution of clinical development programs. The company faces significant execution risk, as clinical-stage biotechnology companies have historically high failure rates, with most drug candidates never reaching market approval. Without established commercial products, proven management execution, or substantial financial resources compared to larger competitors, Genelux's competitive position remains precarious and largely dependent on clinical trial outcomes.
Risks & safety
Genelux presents a high-risk investment profile typical of clinical-stage biotechnology companies, with limited margin of safety for investors. • **Cash Position**: $16.2 million in cash and short-term investments as of Q1 2025, down from $35.9 million in current assets • **Burn Rate**: Operating cash flow burn of approximately $21-29 million annually, suggesting less than one year of runway at current spending levels • **Debt Level**: Minimal debt with debt-to-equity ratio of 0.06, indicating low leverage risk • **Solvency Risk**: High - company will likely need additional financing within 6-12 months to continue operations • **Valuation**: Trading at 2.8x book value with negative earnings, making traditional valuation metrics difficult to assess • **Current Ratio**: Strong at 4.67, indicating good short-term liquidity relative to current liabilities • **Revenue**: Essentially pre-revenue with only $8,000 in annual sales, creating complete dependence on capital markets for funding
Recent development
Based on the available financial data, Genelux has been focused on advancing its clinical pipeline while managing cash resources carefully. The company has maintained a relatively stable cash burn rate of $20-30 million annually while progressing its lead candidate Olvi-Vec through clinical development. The minimal revenue generation of $8,000 in 2024 compared to $170,000 in 2023 suggests the company has been primarily focused on internal development rather than pursuing collaborative or licensing revenue opportunities. The company's asset base has remained relatively stable, with total assets ranging from $35-45 million over the past year, indicating disciplined capital allocation. The maintenance of a strong current ratio above 4.5x demonstrates prudent financial management in preserving liquidity for ongoing operations. However, the declining cash position from previous quarters suggests the company is approaching a critical inflection point where additional financing will be necessary to continue clinical development programs and advance toward potential regulatory milestones.
GNLX company profile · for informational purposes only — not investment advice.
Track GNLX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free